{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:55:22Z","timestamp":1781646922560,"version":"3.54.5"},"reference-count":37,"publisher":"Norwegian Medical Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2014,1,14]]},"DOI":"10.4045\/tidsskr.13.0761","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T08:40:43Z","timestamp":1389775243000},"page":"42-6","source":"Crossref","is-referenced-by-count":4,"title":["Hvordan virker antiepileptika?"],"prefix":"10.4045","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1851-4857","authenticated-orcid":false,"given":"Karl O.","family":"Nakken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-694X","authenticated-orcid":false,"given":"Kjell","family":"Heuser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Alfstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Taub\u00f8ll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Faingold CL. Anticonvulsant drugs as neuronal network-modifying agents. I: Schwartzkroin PA, red. Encyclopedia of basic epilepsy research. Amsterdam: Elsevier, 2009: 50\u2009\u2013\u20098.","DOI":"10.1016\/B978-012373961-2.00074-6"},{"key":"ref=2","unstructured":"Banerjee PN, Hauser WA. Incidence and prevalence. I: Engel J jr., Pedley TA, red. Epilepsy: a comprehensive textbook. 2. utg. Philadelphia, PA: Wolters Kluwer\/Lippincott Williams & Wilkins, 2008: 45\u2009\u2013\u200956."},{"key":"ref=3","unstructured":"Heinemann U, Jones RSG. Neurophysiology. I: Dam M, Gram L, red. Comprehensive epileptology. New York: Raven Press, 1990: 17\u2009\u2013\u200942."},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Porter RJ, Dhir A, Macdonald RL et al. Mechanisms of action of antiseizure drugs. Handb Clin Neurol 2012; 108: 663\u2009\u2013\u200981. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22939059&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/B978-0-444-52899-5.00021-6","DOI":"10.1016\/B978-0-444-52899-5.00021-6"},{"key":"ref=5","unstructured":"White HS, Porter RJ, Kupferberg HJ. Screening of new compounds and the role of the pharmaceutical industry. I: Engel J jr., Pedley TA, red. Epilepsy: a comprehensive textbook. 2. utg. Philadelphia, PA: Wolters Kluwer\/Lippincott Williams & Wilkins, 2008: 1469\u2009\u2013\u200985."},{"key":"ref=6","unstructured":"Sills GJ. Molecular targets of antiepileptic drugs. I: Kahane P, Berg A, L\u00f8scher W et al, red. Drug-resistant epilepsies. Paris: John Libbey Eurotext, 2008: 85\u2009\u2013\u2009105."},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res Brain Res Rev 1998; 26: 16\u2009\u2013\u200928. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9600622&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0165-0173(97)00054-4","DOI":"10.1016\/S0165-0173(97)00054-4"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Stafstrom CE. Persistent sodium current and its role in epilepsy. Epilepsy Curr 2007; 7: 15\u2009\u2013\u200922. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17304346&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1535-7511.2007.00156.x","DOI":"10.1111\/j.1535-7511.2007.00156.x"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Errington AC, St\u00f6hr T, Heers C et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008; 73: 157\u2009\u2013\u200969. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17940193&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1124\/mol.107.039867","DOI":"10.1124\/mol.107.039867"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 2001; 63: 815\u2009\u2013\u200946. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11181977&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1146\/annurev.physiol.63.1.815","DOI":"10.1146\/annurev.physiol.63.1.815"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 2005; 46 (suppl 9): 140\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16302888&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1528-1167.2005.00326.x","DOI":"10.1111\/j.1528-1167.2005.00326.x"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Cunningham MO, Woodhall GL, Thompson SE et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004; 20: 1566\u2009\u2013\u200976. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15355323&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1460-9568.2004.03625.x","DOI":"10.1111\/j.1460-9568.2004.03625.x"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009; 61: 197\u2009\u2013\u2009216. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19443931&dopt=Abstract","DOI":"10.1016\/S1734-1140(09)70024-6"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Nakken KO, Rytter EM, Brockmeier F. Benzodiazepiner i epilepsibehandling. Tidsskr Nor Legeforen 2010; 130: 842\u2009\u2013\u20094. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20418931&dopt=Abstract","DOI":"10.4045\/tidsskr.09.1152"},{"key":"ref=15","unstructured":"Macdonald RL, Rogawski MA. Cellular effects of antiepileptic drugs. I: Engel J jr., Pedley TA, red. Epilepsy: a comprehensive textbook. 2. utg. Philadelphia,PA: Wolters Kluwer\/Lippincott Williams & Wilkins, 2008: 1433\u2009\u2013\u200945."},{"key":"ref=16","unstructured":"Ben-Menachem E, Dulac O, Chiron C. Vigabatrin. I: Engel J jr., Pedley TA, red. Epilepsy: a comprehensive textbook. 2. utg. Philadelphia, PA: Wolters Kluwer\/Lippincott Williams & Wilkins, 2008: 1683\u2009\u2013\u200993."},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Meldrum BS, Chapman AG. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 1999; 40 (suppl 9): S2\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10612355&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1528-1157.1999.tb02087.x","DOI":"10.1111\/j.1528-1157.1999.tb02087.x"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Ben-Ari Y, Khalilov I, Kahle KT et al. The GABA excitatory\/inhibitory shift in brain maturation and neurological disorders. Neuroscientist 2012; 18: 467\u2009\u2013\u200986. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22547529&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177\/1073858412438697","DOI":"10.1177\/1073858412438697"},{"key":"ref=19","unstructured":"Nakken KO, Johannessen SI. Anfallsforverring for\u00e5rsaket av antiepileptika. Tidsskr Nor Legeforen 2008; 128: 2052\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18846119&dopt=Abstract"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Sveinbjornsdottir S, Sander JW, Upton D et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 1993; 16: 165\u2009\u2013\u200974. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8269915&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/0920-1211(93)90031-2","DOI":"10.1016\/0920-1211(93)90031-2"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Synowiec AS, Singh DS, Yenugadhati V et al. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res 2013; 105: 183\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23369676&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.eplepsyres.2013.01.007","DOI":"10.1016\/j.eplepsyres.2013.01.007"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Taub\u00f8ll E, Gjerstad L. Effects of antiepileptic drugs on the activation of glutamate receptors. Prog Brain Res 1998; 116: 385\u2009\u2013\u200993. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9932390&dopt=Abstract","DOI":"10.1016\/S0079-6123(08)60450-1"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Hassel B, Iversen EG, Gjerstad L et al. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J Neurochem 2001; 77: 1285\u2009\u2013\u200992. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11389179&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1046\/j.1471-4159.2001.00349.x","DOI":"10.1046\/j.1471-4159.2001.00349.x"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011; 11: 56\u2009\u2013\u200963. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21686307&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.5698\/1535-7511-11.2.56","DOI":"10.5698\/1535-7511-11.2.56"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Hanada T, Hashizume Y, Tokuhara N et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011; 52: 1331\u2009\u2013\u200940. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21635236&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1528-1167.2011.03109.x","DOI":"10.1111\/j.1528-1167.2011.03109.x"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Ceolin L, Bortolotto ZA, Bannister N et al. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 2012; 61: 517\u2009\u2013\u200922. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22433907&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.neuint.2012.02.035","DOI":"10.1016\/j.neuint.2012.02.035"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013; 54: 117\u2009\u2013\u200925. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22905857&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1528-1167.2012.03638.x","DOI":"10.1111\/j.1528-1167.2012.03638.x"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Lynch BA, Lambeng N, Nocka K et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101: 9861\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15210974&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1073\/pnas.0308208101","DOI":"10.1073\/pnas.0308208101"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Kaminski RM, Gillard M, Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs. I: Noebels JL, Avoli M, Rogawski MA, red. Jasper's Basic mechanisms of the epilepsies. 4. utg. Bethesda, MD: National Center for Biotechnology Information, 2012.","DOI":"10.1093\/med\/9780199746545.003.0076"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Aggarwal M, Kondeti B, McKenna R. Anticonvulsant\/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat 2013; 23: 717\u2009\u2013\u200924. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23514045&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1517\/13543776.2013.782394","DOI":"10.1517\/13543776.2013.782394"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Heuser K, Szokol K, Taub\u00f8ll E. Gliacellenes rolle ved epilepsi. Tidsskr Nor Legeforen 2014; 134: 37 \u2013 41.","DOI":"10.4045\/tidsskr.12.1344"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Devinsky O, Vezzani A, Najjar S et al. Glia and epilepsy: excitability and inflammation. Trends Neurosci 2013; 36: 174\u2009\u2013\u200984. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23298414&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.tins.2012.11.008","DOI":"10.1016\/j.tins.2012.11.008"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia 2010; 51: 27\u2009\u2013\u200936. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19817806&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1528-1167.2009.02341.x","DOI":"10.1111\/j.1528-1167.2009.02341.x"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Syvertsen MR, Markhus R, Selmer KK et al. Juvenil myoklonusepilepsi. Tidsskr Nor Legeforen 2012; 132: 1610\u2009\u2013\u20093. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22875125&dopt=Abstract","DOI":"10.4045\/tidsskr.11.1518"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Bremer A, Lossius MI, Nakken KO. Dravet syndrome \u2013 considerable delay in making the diagnosis. Acta Neurol Scand 2012; 125: 359\u2009\u2013\u200962. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22050316&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1600-0404.2011.01609.x","DOI":"10.1111\/j.1600-0404.2011.01609.x"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 2004; 75: 1376\u2009\u2013\u200981. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15377680&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/jnnp.2004.045690","DOI":"10.1136\/jnnp.2004.045690"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Brigo F, Ausserer H, Tezzon F et al. When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy. Epilepsy Behav 2013; 27: 439\u2009\u2013\u200942. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23591263&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.yebeh.2013.03.010","DOI":"10.1016\/j.yebeh.2013.03.010"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:16:08Z","timestamp":1781644568000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2014\/01\/oversiktsartikkel\/hvordan-virker-antiepileptika"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,14]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1,14]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.13.0761","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,14]]}}}